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Pericytes were ﬁrst characterized in the 19th century by Rouget as a
mural cell population embedded in the basementmembrane of venules
and capillaries (Bergers and Song, 2005). Due to their perivascular posi-
tion, Rouget cells were renamed as pericytes by Zimmermann. Initially,
pericytes were believed to be involved in vasoconstriction. However, in
the last ﬁfty years, the functional properties of pericytes have greatly
expanded.
In general, pericytes are involved in the preservation of vascular
rheology and homeostasis, including regulation of blood ﬂow, angio-
genesis, structural stabilisation of the vasculature, and vascular per-
meability (Hellstrom et al., 2001; Pallone and Silldorff, 2001; Enge
et al., 2002). However, they can also acquire tissue-speciﬁc roles. In
the central nervous system (CNS) and retina, the ratio of pericytes
to endothelial cells (ECs) is 1:1, forming the so-called blood-brain
barrier (BBB) and blood-retinal barrier (BRB) (Shepro and Morel,
1993). This pericyte density is essential to form a ﬁlter to protect
brain and retina cells from potentially toxic blood-derived factors.
In the kidney, pericytes are highly specialised cells which account
for 30% of the total tissue population and are involved in the regula-
tion of ultraﬁltration at the glomerulus (Armulik, Abramsson, and
Betsholtz, 2005). In fenestrated endothelium found in organs such
as the liver, pericytes – here designated hepatic stellate cells – are
important in the remodelling of the extracellular matrix (ECM)
(Kitano and Bloomston, 2016). In bone marrow endothelium,
pericytes have a role in maintaining the homeostasis of the vascular
niche (Corselli et al., 2013a). Emerging evidence demonstrates the
involvement of pericytes in immunomodulatory and phagocytic ac-
tivity (Tu et al., 2011). This plethora of tissue-speciﬁc properties
demonstrates a high degree of functional plasticity, demanding a
more detailed characterization of pericytes.
1.1. Pericyte reworked: the perivascular cell world
Due to the heterogeneity of the pericyte population, there is an in-
tense debate as to the deﬁnition of pericyte phenotypic characteristics,
as well as their potential origin. The common characteristics shared
among pericytes are their perivascular position, as determined by elec-
tron microscopy, and the ubiquitous expression of platelet-derived
growth factor receptor β (PDGFRβ) and CD146 (Crisan et al., 2008).
However, pericytes also express divergentmarkers based upon their lo-
cation; arterial pericytes express neural/glial antigen 2 (NG2) and α
smooth muscle actin (α-SMA), while those localised to the capillary
lack these markers (Crisan, Corselli, Chen, and Peault, 2012).
In recent years, a pericyte-like population has been characterized in
the tunica adventitia of vessels in different tissues (Campagnolo et al.,
2010; Corselli et al., 2012; Avolio et al., 2015; Kramann et al., 2016).
These populations share part of their antigenic proﬁle with
conventionally-deﬁned pericytes, including NG2/CSPG4 and PDGFRβ,
but do not express CD146. Notably, they can express CD34, a typical
marker of hematopoietic progenitor cells (Traktuev et al., 2008). To
what extent this adventitial population should be considered related
to microvascular pericytes remains uncertain. Both pericytes and ad-
ventitial cells have been demonstrated to commit to different mature
mesoderm-like lineages (such as osteoblast, chondrocyte, and adipo-
cyte), (Paquet-Fiﬁeld et al., 2009; Dellavalle et al., 2011; Katare et al.,
2011; Park et al., 2011; Paul et al., 2012), thus suggesting a multipotent
capability similar tomesenchymal stromal cells (MSCs) (Bara, Richards,
Alini, and Stoddart, 2014). Accordingly, thewhole perivascular cell pop-
ulation has been suggested to be the in situ equivalent of MSCs, while
MSCs have been proposed as the in vitro counterpart of pericytes
(Crisan et al., 2008). However, the International Society for Cell Therapy
states that MSCs represent a heterogeneous cell population with differ-
ent differentiation capabilities (Dominici et al., 2006) and Blocki et al.
have recently demonstrated that not all MSCs can differentiate intopericyte-like cells (Blocki et al., 2013). In this context, Birbrair et al.
have characterized in vitro two distinct pericyte populations: type-1
pericytes, able to generate adipocyte and ﬁbroblasts but not neural
cells, and type-2, characterized by neurogenic and myogenic potential
(Birbrair et al., 2014). Moreover, in situ characterization of MSCs dem-
onstrates that those expressing CD146 resemble pericytes in their
localisation (peri-endothelial) and their angiocrine activity (Corselli
et al., 2013b). Therefore, pericytes and adventitial progenitor cells can
be grouped as perivascular stem cells (PSCs) according to a) their
localisation and b) their multipotency (James et al., 2012; Askarinam
et al., 2013; Chung et al., 2015).
The theory that pericytes are merely supportive perivascular cells
can now be considered obsolete. According to the characteristics de-
scribed above, these cells should be considered as heterogeneous,
tissue-speciﬁc, and multipotent populations. The aim of this review,
therefore, is to provide a general description of the perivascular cell
population, highlight their recently described roles in the development
of different pathophysiological processes and discuss how this is being
exploited in pericyte-targeted therapies.
2. Diabetes
2.1. Diabetic retinopathy
Diabetic retinopathy (DR) is a major complication of diabetes. In the
UK, diabetes is the leading cause of blindness. Patients suffering fromdi-
abetes have a 10 to 20 times increased risk of developing blindness
compared to non-diabetic individuals. DR symptoms include blurred vi-
sion, the appearance of dark spots, the perception of “ﬂoaters” in the
ﬁeld of vision, eye pain, double vision, reduction in low-light perception,
sudden vision loss, and complete blindness. Risk factors for DR include
high blood pressure, hyperglycemia, hyper- or dyslipidemia, ethnicity,
as well as the type of diabetes. Within the ﬁrst 2 decades after disease
onset, nearly all type 1 diabetic (T1D) patients will develop retinopathy,
comparedwith 60% of type 2 diabetic (T2D) patients (Fong et al., 2004).
DR can be described as a microvascular disease that eventually
affects all cell types in the retina. The pathology develops in two dif-
ferent stages: non-proliferative diabetic retinopathy (NPDR) and
proliferative diabetic retinopathy (PDR) (Fig. 1). NPDR is the earli-
est stage of the disease and can be classiﬁed in four forms: mild,
moderate, severe and very severe. NPDR patients' retinas exhibit
microaneurysms, microhemorrhages, nerve ﬁbre infarcts (also
known as cotton wool spots), retinal oedema, and intraretinal vas-
cular abnormalities. On the cellular level, NPDR is characterized by
a loss of both pericytes and ECs, causing a decrease in the number
of functional blood vessels as well as disruption of the BRB. Ad-
vanced PDR is characterized by the proliferation of blood vessels
throughout the retina and an increase in basement membrane
thickness. Neovascularization and the related dysregulated endo-
thelial sprouting support the development of highly irregular vas-
cular networks leading to the penetration of the choroid and
vitreous areas of the eye. Vessel invasion can cause obstruction
and even detachment of the retina, leading to blindness. DR can
also lead to diabetic macular oedema (DME), which is characterized
by the swelling of the maculae caused by leaking of ﬂuids from the
aberrant blood vessels. The macular region of the retina is rich in
colour sensing cones, therefore microvascular leakage in this region
leads to disruption of these light-sensing cells and a decrease in vi-
sual perception.
Pericytes are an integral component of both the retina and its micro-
vasculature. The retina is the highest energy-consuming structure in the
human body, requiring even more resources than the brain (Schmidt
et al., 2003). The importance of pericytes to the retinalmicrovasculature
is highlighted by the fact that the ratio of retinal pericytes to ECs is 1:1,
and that they cover 85% of the microvasculature area (Shepro and
Morel, 1993). The pericyte-EC interaction in the retina is a primordial
Fig. 1. Progression of diabetic non-proliferative retinopathy. Progression of early-stage non-proliferative retinopathy to proliferative retinopathy. Elevated glucose levels will cause
apoptotic cell death of pericytes. This will lead to a more permeable blood vessels and subsequent endothelial cells which will increase leakiness of vessels even more. Loss of pericytes
and endothelial will increase ﬂuid leakage in the retina as well as immune cell inﬁltration. These intra-ocular vascular changes will then contribute to the development of proliferative
retinopathy.
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gen, growth and regulatory factors aswell as immune cells from the pe-
riphery into the neuronal environment of the retina. Disruption of
endothelial-pericyte interactions leads to “leaking” of the vasculature
into various regions of the retina and facilitates access of immune and
inﬂammatory cells into the retinal environment.
One of the earliest hallmarks of NPDR is the loss of pericytes. This cell
death causes regression of the microvasculature leading to leaking of
ﬂuids, leukocyte adhesion to the vasculature and hypoxia in the dam-
aged area. The diabeticmicroenvironment seems particularly detrimen-
tal to pericyte survival; during the early stages of retinopathy, the
pericyte to EC ratio decreases from 1:1 to 1:4 (Robison, Kador, and
Kinoshita, 1985).
The high glucose microenvironment in diabetes can directly induce
apoptosis of retinal pericytes (Haribalaganesh, Sheikpranbabu,
Elayappan, Venkataraman, and Gurunathan, 2009). High glucose-
induced cell death is due to an increase in production of reactiveoxygen species (ROS). Increased ROS can disrupt the mitochondrial
membrane, leading to the release of cytochrome C and the activation
of the caspase-3 dependent apoptotic cascade. It has been suggested
that hyperglycemia-related complications are due to the increased pro-
duction of superoxide through an increased output of themitochondrial
electron transport chain (Nishikawa et al., 2000). More recently, it has
been demonstrated that only the inhibition of NADPH oxidase is able
to abrogate hyperglycaemic-related events such as ROS production
and in vitro pericyte apoptosis (Mustapha, Tarr, Kohner, and Chibber,
2010).
Anothermechanism bywhich high glucose-induced oxidative stress
can cause pericyte loss in DR is through the generation of Advanced
Glycation End-Products (AGEs). AGEs are formedwhen reducing sugars
such as glucose react in a non-enzymatic manner with nucleic acids,
proteins, and lipids. Intracellularly, these reactions can result in DNA
and RNA damage, protein crosslinking, and lipid peroxidation, leading
to multiple cytotoxic effects, reviewed in (Singh, Barden, Mori, and
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free-radical formation, which leads to oxidative stress and apoptosis of
retinal pericytes (Assero, Lupo, Anfuso, Ragusa, and Alberghina, 2001).
Extracellular AGEs can also affect pericytes. Receptors of AGEs
(RAGE) are found on most cell surfaces and can exert multiple effects
depending on the cell type. In the case of the retinal microvasculature,
AGE-RAGE binding increases EC proliferation through an autocrine
mechanism involving the mitogen-activated protein kinase (MAPK)
ERK pathway and hypoxia-inducible factor 1α (HIF1α) activation lead-
ing to the expression of vascular endothelial growth factor (VEGF.) AGE-
RAGE interaction also induces VEGF production by retinal pericytes
(Yamagishi et al., 2002b). This increase in VEGF production is one of
the major contributors to the development of PDR and mediates pro-
gression of the disease. Although AGE-RAGE interaction increases reti-
nal EC proliferation, in pericytes it induces apoptosis and is thought to
be a major contributor to the pericyte loss observed in early NPDR. In
vitro, treatment of retinal pericytes with extracellular AGEs causes apo-
ptosis in a dose-dependent manner (Yamagishi et al., 2002b). In vivo,
streptozotocin-induced T1D RAGE−/−mice showed decreased vascular
permeability and retinal acellular capillary formation (McVicar et al.,
2015). Contrary to expectations, diabetic RAGE−/−mice did not exhibit
a decrease in pericyte loss, suggesting that alternative pericyte pro-
apoptotic factors are at work in DR.
The damaging effects of ROS and AGEs are exacerbated by the down-
regulation of expression and/or activity of various anti-oxidant proteins
in the diabetic retina. Nuclear factor (erythroid-derived 2)-like 2 (NRF2)
is responsible for the transcription of a large number of detoxifying en-
zymes, e.g. heme oxygenase and glutathione, and the knockout of NRF2
in diabetic mice causes exacerbation of DR (Xu et al., 2014). It has been
reported that NRF2 nuclear translocation and transcriptional activity is
suppressed in DR both in vivo and in vitro (Zhong, Mishra, and
Kowluru, 2013). Sulforaphane is a known activator of NRF2 both
in vivo and in vitro (Jimenez-Osorio, Gonzalez-Reyes, and Pedraza-
Chaverri, 2015). It has been shown that sulforaphane treatment of bo-
vine retinal pericytes in vitro decreases ROS production and AGE forma-
tion, as well as RAGE mRNA and protein expression (Maeda, Matsui,
Ojima, Takeuchi, and Yamagishi, 2014).
The levels in the aqueous humour of another player in the ROS-
detoxiﬁcation pathway, Pigment Epithelium-Derived Factor (PEDF),
have been positively correlated with the anti-oxidant status of the reti-
na (Yoshida et al., 2007). PEDF levels are decreased in the vitreous of di-
abetic patients with retinopathy compared to healthy subjects (Boehm
et al., 2003b), and are a strong predictor of progression of NPDR (Boehm
et al., 2003a). PEDF hasmultiple roles in themicrovasculature. Increased
production of PEDF has been shown to reduce ROS-induced apoptosis
by stabilising the mitochondria via activation of the PI3K/AKT survival
pathway (He et al., 2014a). PEDF can also act directly on ROS produc-
tion. In cultured retinal pericytes, PEDF treatment reduced the produc-
tion of ROS induced by oxidized low-density lipoproteins (ox-LDL).
PEDF exerts its effects through the blockade of the NF-kappaB pathway
and the transcriptional upregulation of superoxide dismutase (SOD) 1
(Zhang et al., 2008). Similarly, PEDF can abrogate the negative effects
of AGEs through both its anti-oxidant effects and by directly acting on
survival pathways. PEDF treatment increases the expression of the de-
toxifying enzymes SOD and glutathione reductase which impairs the
generation of ROS by AGEs (Maeda et al., 2014). PEDF can also induce
cell survival by activation of the Src kinase pathway (Sheikpranbabu,
Haribalaganesh, and Gurunathan, 2011), as well as by increasing the
levels of the anti-apoptotic protein Bcl-2 (Yamagishi, Inagaki, Amano,
et al., 2002a). Furthermore, PEDF inversely modulates VEGF expression,
by acting as a transcriptional repressor of VEGF in retinal ECs (Zhang,
Wang, Gao, Parke, and Ma, 2006).
While high glucose and AGEs are factors affecting the whole retinal
environment, signals from speciﬁc cells within the retina can also con-
tribute to pericyte loss. The angiopoietin/Tie2 pathway is a central path-
way in pericyte-EC crosstalk and regulation. angiopoietin-1 (Ang1) isexpressed by pericytes while the antagonist, angiopoietin-2 (Ang2)
and its receptor Tie2, are expressed by ECs. In basal conditions, Ang1 se-
creted by pericytes stimulates ECs to produce transforming growth fac-
tor β (TGF-β) and platelet-derived growth factor B (PDGFb). These
factors, in turn, stabilise pericyte-EC interactions (Armulik et al.,
2005), while antagonism of this pathway leads to destabilisation of
pericyte-EC interactions. Ang2 production by ECs is speciﬁcally upregu-
lated during angiogenesis (Gale et al., 2002). It has been shown that
Ang2 protein levels in the diabetic retina can be dramatically increased
compared to non-diabetic controls and that injection of recombinant
Ang2 in the retina causes dramatic pericyte loss (Park et al., 2014).
Park et al. have recently shown that concomitant hyperglycemia and
Ang2 stimulation reduce the p53-dependant apoptosis of retinal
pericytes. Interestingly, Ang2 modulates this process not by interacting
with Tie2, but with the novel α3β1 integrin (Park et al., 2014).
2.2. Diabetic nephropathy
Diabetic nephropathy (DN) resulting from the poor control of circu-
lating glucose levels is a leading cause of chronic kidney disease (CKD)
in the Western world and is responsible for 30–40% of all end-stage
renal disease in the UK (Kidney Research UK, 2015). It is characterized
by persistent high protein levels in the urine (proteinuria;
N300 mg/24 h), progressive decline in the glomerular ﬁltration rate
(GFR) and increased arterial blood pressure. Renal pericytes are partic-
ularly affected by high glucose, leading to the pathology of DN. Current
therapies for the treatment of DN include strict control of blood glucose
by diet and/or administration of insulin, and control of blood pressure
with antihypertensive agents, such as angiotensin-converting enzyme
inhibitors or angiotensin II receptor blockers. While these treatments
can slow the progression of DN, they cannot prevent or reverse it. Cur-
rent clinical trials are focusing on targeting the speciﬁc molecular path-
ways involved in renal oxidative stress and ﬁbrosis, which has recently
been reviewed in detail by Khan and Quaggin (2015).
Renal pericytes are found around the peritubular capillaries that sur-
round the nephron, where the ratio of pericytes to ECs is 1:2.5 (Armulik
et al., 2005). Furthermore, a specialised form of pericyte, known as
mesangial cells, are located in the glomerulus, the ﬁltration unit of the
kidney. There is some debate as to whether glomerular podocytes
could also be classed as a specialised type of pericyte. During develop-
ment, the metanephric mesenchyme differentiates into nephrons,
resulting in both stromal and epithelial lineages. In 1996, Hatini, Huh,
Herzlinger, Soares, and Lai (1996), described that stromal cells, which
become pericytes, vascular smooth muscle cells (VSMCs), and
mesangial cells, express the transcription factor FoxD1. It has subse-
quently been recognised that podocytes also highly express FoxD1, sug-
gesting they descend from the FoxD1 lineage (Brunskill, Georgas,
Rumballe, Little, and Potter, 2011). Podocytes share many characteris-
tics of pericytes and therefore have been included in this review as
pericyte-like cells. Peritubular pericytes, mesangial cells, and podocytes
are all found wrapped around capillaries, embedded in the matrix they
secrete (Diaz-Flores et al., 2009) and form close contacts with the un-
derlying ECs (Kida and Dufﬁeld, 2011). They all have roles in stabilising
the vascular networks (von Tell, Armulik, and Betsholtz, 2006), and
modulating vascular tone (Saleem et al., 2002; Crawford et al., 2012)
and vascular permeability (Satchell et al., 2002).
High glucose causes migration of peritubular pericytes away from
the capillary into the interstitial space. The capillary becomes
destabilised, resulting in microvascular rarefaction. This, in turn, can
lead to tissue hypoxia. The migrating peritubular pericytes are thought
to transform into myoﬁbroblasts, as these cells are not seen in
the healthy kidney. Lin et al. proposed pericytes as the source of
myoﬁbroblasts. They labelled collagen type I producing cells
(peritubular pericytes) in the kidney with green ﬂuorescent protein
and showed that these cells initially expressed typical pericyte markers
(PDGFR-β, CD44, CD90 NG2 and α-SMA), but expression decreased
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Kidney injury upregulated expression of the above genes in pericytes,
in particular α-SMA. It also upregulated other genes associated with
the myoﬁbroblast phenotype, along with an increased production of
matrix proteins, in particular collagen type I. The pericytes migrated
away from capillaries into the interstitial space, where deposition of ex-
cess matrix led to tubulointerstitial ﬁbrosis and loss of organ function
(Lin et al., 2008). It is worth noting that renal ﬁbrosis is not only seen
in response to DNbut also in other types of kidney injury, such as unilat-
eral ureteral ligation and ischemia-reperfusion injury.
In the glomerulus, where mesangial cells constitute 30% of all glo-
merular cells (Schlondorff, 1987), DN is characterized by mesangial
cell hypertrophy, proliferation, and an increase in production of
mesangial matrix (e.g.: type IV collagen, laminin and ﬁbronectin)
(Stratman, Malotte, Mahan, Davis, and Davis, 2009). Cellular hypertro-
phy is thought to result fromhigh glucose-induced expression of a num-
ber of growth factors, including Ang-2 and TGF-β, which causes protein
kinase C (PKC) activation (Li et al., 2007). Brosius et al. also suggest the
involvement of mTOR in activating pro-growth and antiapoptotic path-
ways (Brosius, Khoury, Buller, and Chen, 2010). Meanwhile, Liu et al.
(2012a) have shown that increased activity of mTOR, via downregula-
tion of Cx43, leads to mesangial hypertrophy in response to high
glucose.
Many of the symptoms of DN can be related to an increase in matrix
production by renal pericytes (both peritubular and mesangial cells) in
response to oxidative stress caused by high glucose. For a comprehen-
sive review of oxidative stress signaling in DN refer to this review by
Manda, Checherita, Comanescu, and Hinescu (2015). Brieﬂy, high glu-
cose causes the formation of AGE, which in turn increases ROS produc-
tion, leading to activation of a number of signaling pathways, via PKC
(Coughlan et al., 2009). High glucose can directly activate PKC or indi-
rectly through the AGE/ROS axis. This causes activation of MAPK signal-
ing pathway resulting in increased expression of matrix proteins
(Lander et al., 1997), and also inhibition of expression of genes involved
in matrix degradation, such as matrix metalloproteinases (MMPs)
(Fiorentino et al., 2013). Furthermore, MAPK and extracellular ROS
can upregulate TGF-β expression in peritubular pericytes, podocytes
and mesangial cells (Iglesias-de la Cruz et al., 2002; O'Donovan et al.,
2012). TGF-β is thought to be a major pro-ﬁbrotic factor in DN, causing
increased expression of both collagen type IV and ﬁbronectin (Ziyadeh
et al., 2000; Iglesias-de la Cruz et al., 2002), while inhibitingmatrix deg-
radation. The increased deposition of matrix by peritubular pericytes
causes tubulointerstitial ﬁbrosis, as described above, and may occlude
the lumen of the peritubular capillaries and glomerulus leading to an in-
crease in blood pressure. Furthermore, in the case of mesangial cell ma-
trix expansion, it may affect the GFR by causing glomerular scarring
(glomerular sclerosis) and reducing the surface area for glomerular
ﬁltration.
High glucose causes changes in podocyte morphology by altering
the actin cytoskeleton (Lv et al., 2016) and podocyte loss by the detach-
ment of podocytes from the basementmembrane (Dessapt et al., 2009)
or by apoptosis (Susztak, Raff, Schiffer, and Bottinger, 2006). Each of
these results in increased proteinuria and decreased GFR, because
podocytes are terminally differentiated and therefore unable to repli-
cate (Shankland and Al'Douahji, 1999). Mechanisms for glucose-
mediated podocyte apoptosis are thought to be mediated through in-
duction of ROS by NADPH oxidase and AGE (Eid et al., 2009) (as
discussed above), leading to increased intracellular calcium and apopto-
sis (Liu et al., 2013). There are also suggestions that TGF-β can reduce
podocyte attachment to the glomerular basement membrane (GBM)
by downregulating expression of integrins, in particular α3β1 integrin
(Dessapt et al., 2009). ROSover-activationmay also cause the remaining
podocytes to increase production of the basementmembrane, causing it
to thicken. Interestingly, podocytes express the insulin receptor
(Coward et al., 2005) and podocyte-speciﬁc deletion of the insulin re-
ceptor results in proteinuria, increased glomerular matrix, thickenedGBM, and changes in podocyte morphology and effacement (Welsh
et al., 2010). This suggests some of the podocyte-related changes seen
in DN could be as a result of impaired podocyte insulin signaling.
Similar to pericytes of the retina, podocytes produce VEGF-A. How-
ever, here it is primarily involved in regulating capillary permeability
(Eremina et al., 2003), rather than neovascularisation. It does this by sig-
naling through VEGFR-2, which is mainly expressed by glomerular ECs.
In DN, there is evidence that either toomuch or too little VEGF-A can be
pathological. Overexpression is generally seen at the start of the disease,
causing GBM thickening, mesangial expansion, podocyte effacement,
detachment, and increased proteinuria (Veron et al., 2010). As the dis-
ease progresses, VEGF-A expression decreases to below the normal
range (possibly due to the loss of podocytes) and results in increased
proteinuria (Baelde et al., 2007). Work by Jin et al. (2012) has described
how the deletion of the soluble form of the VEGF receptor (sFlt1) from
podocytes caused reorganisation of the podocyte actin cytoskeleton
and proteinuria. This further demonstrates the importance of VEGF
and its receptors in pericyte biology. This effect was not just localised
to renal pericytes. When sFlt1 was silenced in the lung, trachea or reti-
nal pericytes, vascular defects were observed, underlining the impor-
tance of pericytes in the maintenance of vascular structure in the
microcirculation. Studies by Lin et al. (2011) have demonstrated the im-
portance of cross-talk between ECs and pericytes tomaintain the vascu-
lar structure. Blocking VEGFR-2 on ECs enhanced pericyte detachment
after injury and increased ﬁbrosis. However, blockade of PDGFR-β pro-
duction by pericytes in response to injury prevented pericyte detach-
ment and reduced ﬁbrosis. These ﬁndings suggest modulation of
growth factor cross-talk between the cells may offer a novel therapeutic
approach for kidney injury and other pathologies relating to microvas-
cular defects.2.3. Diabetic neuropathy
Diabetic neuropathies are a heterogeneous group of disorders that
include diabetic peripheral neuropathies (DPN) and diabetic autonomic
neuropathy (DAN). These result frommetabolic injuries causing diffuse
andwidespread damage to peripheral and autonomic nerves (Vinik and
Erbas, 2013).
Previous studies have shown DPN to be associated with lower limb
pain, neural desensitisation, foot/leg abscesses, potentially resulting in
the eventual amputation of lower limbs. Similarly, DAN has been
shown to induce symptoms in the parasympathetic and sympathetic
systemswhich can result in cardiac anomalies such asmyocardial ische-
mia and sudden death (Pop-Busui, Sima, and Stevens, 2006). Moreover,
both DAN and DPN patients exhibit functional and structural impair-
ments in peripheral nerves, caused by oxidative stress, AGE accumula-
tion, glucose toxicity and hypoxia, all eventually leading to neuronal
apoptosis. The hypoxic conditions observed in diabetic neuropathy are
directly related to microangiopathies of the endoneurial capillaries.
Nerve biopsies have shown a decrease in both pericytes and ECs in
endoneurial capillaries, (Yasuda and Dyck, 1987). Arguably, the loss of
pericytes leads to loss and disorganisation of ECs, resulting in decreased
perfusion of peripheral nerves and consequent hypoxia.
Additionally, previous studies have shown that under anoxic condi-
tions electrophysiological parameters of nerve conduction undergo a
decrease in both velocity and amplitude, which relates to the loss of
feeling in the lower extremities (Punsoni, Drexler, Palaia, Stevenson,
and Stecker, 2015). These changes in conduction are associated with
structural changes including demyelinated axons and a decreased
nerve ﬁbre density, exacerbated by hyperglycemia (Punsoni et al.,
2015). Oxygen starvation of nerve ﬁbres leads to oxidative stress due
to a shift towards anaerobic energy metabolism. Consequent ROS pro-
duction leads to the activation of apoptotic pathways resulting in
Schwann cell death and therefore disrupted neural conduction (Ma
et al., 2013).
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One of themost common but least understood complications arising
fromdiabetes is erectile dysfunction (ED). Diabetic patients have a three
times greater risk of developing ED (McKendry et al., 1983), while also
being the most resistant to phosphodiesterase-5 inhibitor treatment
(Martinez Jabaloyas, Gil Salom, Pastor Hernandez, Villamon Fort, and
Garcia Sisamon, 2002). Classic anti-ED drugs such as sildenaﬁl target
the nitric oxide synthesis pathway leading to the release of NO from
ECs, which causes VSMC relaxation. The pathobiology of diabetic ED
does not appear to be due to aberrant NO production, but instead to en-
dothelial dysfunction resulting in leaky endothelium and deregulation
of VSMC contractility (Castela and Costa, 2016). There are very few
studies concerning the role of pericytes in erectile dysfunction. It has
been shown that both in humans and mice, penile pericytes are princi-
pally located in the subtunical area of the corpus cavernosum in the pe-
riphery of the erectile tissue (Yin et al., 2015). In STZ-induced diabetic
mice, a signiﬁcant decrease in penile pericyte number was observed
compared to the control group. This phenomenon was associated with
an increase in corpus cavernosum sinusoidal permeability. Notably, an
increase in ox-LDL extravasation has been observed in the corpus
cavernosum of diabetic mice (Batbold et al., 2016). Ox-LDL has been
linked to inﬂammation and ﬁbrosis which could impair erectile tissue
expandability.
3. Involvement of pericytes in ischemic pathophysiology
Ischemia is caused by inadequate arterial blood ﬂow to a speciﬁc
organ,which leads tomultiple degenerative cellular phenomena, name-
ly ﬁbrosis, necrosis, and apoptosis. In extreme cases, these cellular phe-
nomena are translated to organ function disruption and organ failure.
Pericytes have an important role in the etiology of ischemic organ
failure.
Inmyocardial ischemia, pericytes have been shown to be involved in
ﬁbrosis and scar formation. Using a cardiac ischemia-reperfusion (I-R)
injurymousemodel it was demonstrated that ischemia results in short-
ening of pericyte extension processes and elevated expression of
p75NTR. Low expression of p75NTR in the microvasculature has been
associated with smaller infarct size in animal models. An increased ex-
pression in cardiacmicrovascular pericytes could lead to cardiac ﬁbrosis
(Siao et al., 2012). It was also shown that type-1 pericytes were recruit-
ed to scar tissue after myocardial infarction (MI) but did not contribute
to collagen type 1 production leading to ﬁbrosis (Birbrair et al., 2014).
Fate-tracing experiments in the AT2-induced hypertensive heart
disease mouse model and the AAC injury model showed that Gli1+
cells differentiated into α-SMA+ myoﬁbroblasts in the perivascular
and interstitial spaces. These Gli1+ cells were MSC-like perivascular
cells that express MSCmarkers, possess trilineage potential and include
a small fraction of pericyte-like PDGFRB+ cells. Further analysis re-
vealed that approximately 60% of Gli1+ cells had the propensity to dif-
ferentiate into cardiac myoﬁbroblasts (Kramann et al., 2015).
Interestingly, pericytes seem to be a major contributor to the pro-
duction of myoﬁbroblastic cells and scar formation in the ischemic kid-
ney. Acute or chronic kidney injury/disease is characterized by the
formation of ﬁbrotic tissue in the interstitial spaces in the kidney.
There have been contradicting views about the origin of myoﬁbroblasts
involved in scar tissue formation during tissue repair. Early in vivo stud-
ies have shown that myoﬁbroblasts were derived from multiple cell
types but not pericytes. Studies performed by genetic labeling of cells
in mouse models demonstrated that the production of myoﬁbroblasts
during kidney injury derived from 50% resident ﬁbroblasts, 35% bone
marrow cells, 10% tubular epithelial cells and 5% ECs (Hall et al.,
2014). Fibrosis is the result of cell proliferation, differentiation, and ep-
ithelial and endothelial to mesenchymal transition. However, further
lineage analysis of FoxD1 (LeBleu et al., 2013) and coll1a1
(Humphreys et al., 2010) reporter mice with unilateral uretericobstruction (UUO) and I/R injury have demonstrated that pericytes/
perivascular cells are the major source of myoﬁbroblasts resulting in
scar tissue formation (Lin et al., 2008).
In cerebral ischemia, the involvement of pericytes in the pathophys-
iology seems less clear. Amousemodel of stroke showed that Nox4was
upregulated in cells expressing PDGFRβ, a pericyte marker. Upregula-
tion of Nox4 in pericytes resulted in increased MMP-9 production,
bringing about the breakdown of the BBB (Birbrair et al., 2014). It has
also been shown that during ischemia neurones secrete signals to
pericytes lining the cerebral capillaries. These signals cause the constric-
tion of vessels followed by their rapid death (Hill et al., 2015). This claim
is currently being challenged, as in vivo imaging of double transgenic
mice expressingmCherry driven by theα-SMA promoter and endothe-
lial GFP driven by the Tie2 promoter (SMA-mCherry:Tie2-GFP) showed
that capillary pericytes lackα-SMA and are non-contractile in vivo. They
are distinctly different from arteriolar VSMCs that are contractile in na-
ture. This was conﬁrmed by in vivo optogenetic stimulation of cells lin-
ing the vessels. Activation of VSMCs covering arterioles caused vessel
constriction and reduced cerebral blood ﬂow compared to stimulation
of pericytes in capillaries where no vessel constriction occurred. This
study appears to eliminate pericyte involvement in the early stages of
cerebral ischemia (Nishimura et al., 2015).
4. Pericytes and tumours
Originally, pericyteswere believed to contribute to tumour develop-
ment by participating in angiogenesis. In recent years, however, new
evidence supports the concept of pericytes as one of themain regulators
of the tumour microenvironment (TME) through angiogenesis, metas-
tasis, and participation in the cancer stem cells (CSCs) pool.
4.1. Pericyte tumours
In 2013 theWHO revised the criteria for the classiﬁcation of soft and
bone tissue tumours. Hemangiopericytoma (HPC) is no longer classiﬁed
as a pericyte-derived tumour because it is now known to derive from a
variety of different cell types (Jo and Fletcher, 2014). Spindle cell lesions
known as HPC are now considered as a variety of solitary ﬁbrous tu-
mour (SFT), unrelated to pericytes (Schweizer et al., 2013). Currently,
only glomus tumour and myopericytoma are considered as true
pericyte-derived tumours. Both tumours share the tendency to grow
in a perivascular position and have evidence of myoid differentiation
(Jo and Fletcher, 2014). Glomus tumour is a rare neoplasm arising
from the thermoregulatory glomus body, with an even rarer malignant
variant. It shows a perivascular growth pattern and usually expresses
pericyte markers such as vimentin and α-SMA (but rarely desmin),
and numerous superﬁcial pinocytotic vesicles (Mravic et al., 2015). Sim-
ilarly, myopericytoma is characterized by α-SMA, occasionally desmin
and CD34, but is negative for protein S100 and cytokeratin (Terada,
2010, 2012). Both tumours demonstrate positivity for CD146 and
PDGFRβ, supporting the idea that they are pericyte-derived tumours
(Shen et al., 2015). The malignant forms show a decreased expression
of pericyticmarkers suggesting that they becomemore undifferentiated
cancer cells (Shen et al., 2015).
4.2. Pericyte density: role in tumour growth
Alterations in pericyte density appears particularly important as a
prognostic marker in cancer (O'Keeffe et al., 2008; Cao et al., 2013; Xu
et al., 2014). High pericyte coverage has been associated with forms of
cancers that are the most aggressive and refractory to therapy
(Furuhashi et al., 2004; Yonenaga et al., 2005).
In tumours, EC-mediated pericyte recruitment can be altered,
resulting in different scenarios ranging from high to low pericyte cover-
age. As in the physiological state, PDGFb represents the main chemo-
attractant for perivascular cells in cancer angiogenesis (Furuhashi
Fig. 2. Interaction between pericytes and other vascular players in tumour. In normal condition ECs are stabilised by surrounding pericytes. In tumour this balanced is altered. A) In
tumoural angiogenesis, pericytes could be recruited on site and stabilise the new formed vasculature via VEGF secretion. This can contribute to nourish the cancer cells, favouring
tumour growth. Cancer cells can contribute to this process directly localizing in perivascular position. CSCs have the ability to differentiate in functional pericytes. B) Tumoural
angiogenesis is highly disorganised, morphological changes do not allow cell-to-cell contact either between EC themselves or ECs and pericytes. The increase in vascular permeability
facilitate the intravasion of cancer cells into the bloodstream. Hypoxia is a key condition for EMT to happen, promoting cancer cell mobilization. C) Drug resistance to anti-angiogenesis
treatment can be due to pericytes. Therapy targeting ECs leave pericytes alive, forming a frame to be repopulated by ECs. Even in a combined strategy versus ECs and pericytes, CSCs in
perivascular position can continue to act as pericytes.
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in pericyte recruitment are heparin-binding EGF-like growth factor
(HB-EGF) (Nolan-Stevaux et al., 2010; Cascone et al., 2011), EC secreted
SDF-1 (Song et al., 2009; Chen et al., 2012), and MMP-mediated ECM
degradation (Chantrain et al., 2006). In addition, pericyte-derived
VEGF and Ang-1 can nourish ECs, stabilising the vasculature and
favouring tumour growth (Franco, Roswall, Cortez, Hanahan, and
Pietras, 2011) (Fig. 2A).
Morphological changes, such as the discontinuity of endothelial
basement membrane or multi-layered ECs, prevent pericytesmaking
proper contact with ECs (Folkman, 2002; Baluk, Morikawa, Haskell,
Mancuso, and McDonald, 2003; Krishna Priya et al., 2016). Thus
pericytes are forced away from the perivascular position, resulting
in a leaky vessel (Glentis, Gurchenkov, and Matic Vignjevic, 2014)
(Fig. 2B). Changes in the expression of adhesion molecules and se-
creted factors by pericytes can also contribute to tumourigenesis
and tumour maintenance. In particular, the Notch pathway seems
to be implicated in EC-pericyte interactions and stabilisation of the
vasculature (Pedrosa et al., 2015). In the tumour microenvironment,
reduced pericyte density leads to hypoxia, which triggers endotheli-
al HIF-1α expression through a VEGF-mediated mechanism, pro-
moting disorganised new vessel formation (Chen, Silva, Yuen, and
Mooney, 2007).Low pericyte density can also be associated with increased metasta-
sis. This was elegantly demonstrated in a seminal paper from Xian et al.,
inwhich knocking out the adhesionmolecule NCAM in amouse tumour
model was associatedwith increasedmetastasis (Xian et al., 2006). This
observation has been conﬁrmed in different tumours in which low
pericyte coverage leads to increased tumour cell invasiveness, while a
high coverage is correlatedwith a lowered rate ofmetastatic dissemina-
tion (Yonenaga et al., 2005; Ito et al., 2013; Jayasinghe, Simiantonaki,
and Kirkpatrick, 2015; Zang et al., 2015; Correa, Somoza, Lin,
Schiemann, and Caplan, 2016).
Pericyte loss can also trigger epithelial-mesenchymal transition
(EMT). This consists of the loss of epithelial features (cell polarity,
basal lamina and adherens, tight, and gap junctions) followed by the ac-
quisition of mesenchymal characteristics (spindle shape morphology,
expression of ﬁbronectin, vimentin, and N-cadherin) (Agrawal et al.,
2014).
Moreover, high pericyte coverage could represent an obstacle for
pericyte mimicry by CSCs. CSCs are a group of cancer cells characterized
by the ability to self-renew and initiate tumour formation (Gupta,
Chaffer, andWeinberg, 2009; Welte, Adjaye, Lehrach, and Regenbrecht,
2010). They also have the capacity to transdifferentiate to endothelial
cells and pericytes, contributing to new vessel formation (Ricci-Vitiani
et al., 2010; Wang et al., 2010; Cheng et al., 2013). Recent studies have
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pericyte lineage either in vitro or in vivo (Scully et al., 2012; Cheng
et al., 2013;Mao et al., 2013). Hence, GSCs are able to create a favourable
TME which in turn facilitates tumour progression and dissemination.
Not surprisingly, the most aggressive forms of glioma are characterized
by pericyte hyperplasia (Xu et al., 2014).
4.3. Pericyte-mediated immunomodulation
Due to their close relationshipwithMSCs,which have immunomod-
ulatory properties, it is not surprising that a growing body of evidence is
emerging demonstrating how perivascular cells can also play a pivotal
role in the recruitment and modulation of immune cells in the context
of tumour formation.
Recent ﬁndings suggest that in tumours pericytes can act as immu-
nomodulators of different leukocyte populations, with opposing results.
Tumour-derived pericytes have the ability to negatively inﬂuence CD4+
lymphocyte proliferation and activation (Bose et al., 2013). In human
malignant glioma, perivascular cell-like MSCs negatively correlated
with CD8+ T cells, showing the ability to abrogate the CD8+ T cell re-
sponse (Ochs et al., 2013). However, a xenotransplanted tumour in a
pericyte-deﬁcient mouse model showed a drastically increased recruit-
ment of myeloid-derived suppressor cells (MDSC), an immature cell
population inhibiting T-cell activation and proliferation. Restoring the
normal pericyte coverage abrogated the increased MDSC trafﬁcking in
pericyte-deﬁcient tumours (Hong et al., 2015). As mentioned above
for tumour growth and metastasis, these ﬁndings demonstrate that
pericytes can acquire different roles depending on their abundance
and/or functionality.
5. Pericyte-targeted therapies: state-of-the-art and new frontiers
As discussed, pericytes exert a multitude of effects in many patholo-
gies. However, as the importance of pericyte function in disease is a rel-
atively recent discovery, only a few therapeutic strategies have
speciﬁcally targeted pericytes.
A direct way to slow the progression of DR is to replace the pericytes
lost in the early stages of NPDR. AdultMSCs isolated from the bonemar-
row can act as pericytes in certain conditions (Caplan, 2015). The
RETICELL clinical trial is currently establishing whether an intravitreal
injection of adult bone marrow MSCs to patients with retinitis
pigmentosa can restore ocular function. This study has demonstrated
that patients injected with MSCs have an increased quality of life up to
3 months after injection. Unfortunately, this effect is not detectable
12 months after treatment (Siqueira et al., 2015). In two studies of dif-
ferentmousemodels of DN (T1D and T2D), injection of adult bonemar-
rowMSCs have been shown to improve glomerularmorphology, reduce
mesangial thickening and limit macrophage invasion (Lee et al., 2006;
Ezquer et al., 2009). These studies demonstrate that MSC/pericyte cell
therapy to be a potentially efﬁcacious method of curing diabetic
nephropathy.
The angiogenic factor VEGF plays a major role in PDR and in tumour
vasculogenesis, hence this factor has therefore been identiﬁed as a
major target for therapeutics. The aim is to inhibit unrestrained endo-
thelial sprouting and consequent uncontrolled neovascularisation. A
current trend in DR therapeutic development is the generation of
high-speciﬁcity, high-afﬁnity antibodies targeting and inhibiting
VEGF-A. Treatment with these antibodies has shown efﬁcient restora-
tion of ocular function in patients with DME (Wells et al., 2016). A
long-term clinical trial testing the efﬁcacy of the anti-VEGF
Ranibizumab in patients with DME has also shown improved vision,
sustained during the 5-year treatment programme (Elman et al., 2015).
Another strategy in DR is to limit the generation of ROS, which cause
pericyte loss. PEDF is a secreted factor with potent antioxidant and anti-
angiogenic capabilities mediated via the inhibition of VEGF expression
(Yamagishi et al., 2002a; Zhang et al., 2006). A study using a solutionof recombinant PEDF peptide applied topically to the eye of diabetic
Akita mice showed promising results. The use of PEDF “eye drops” di-
minished pericyte cell death, vascular leakage, and inﬂammation in
the retina (Liu et al., 2012b).
In diabetic nephropathies, pericyte-related therapies mainly focus
on the inhibition of ﬁbrosis. One of the protein targets for ﬁbrosis abro-
gation is PDGF. PDGF is an important mediator of pericyte-
myoﬁbroblast transition and has been singled out as an important tar-
get in various ﬁbrotic kidney diseases (Lin et al., 2008; Chen et al.,
2011; Chang, Chou, Chen, and Lin, 2012). Imatinib is a receptor tyrosine
kinase inhibitor (RTK) speciﬁc for PDGFr and c-Abl. In an obese and di-
abetic mouse model, Imatinib protects against renal injury caused by
themetabolic syndrome. Furthermore, Imatinib can also rescue the glo-
merular and tubule-interstitial structural damage caused by T2D aswell
as ameliorating albuminuria (Lassila et al., 2005).
In the case of tumour angiogenesis, an immense amount of resources
have been dedicated to inhibiting or even removing the ECs at the heart
of vasculogenesis. The most common type of treatment is, as with DR,
anti-VEGF therapy, where the use of VEGF antibodies or antagonists
for the VEGF receptor are administered to the patient. Anti-VEGF thera-
py is efﬁcient acutely, but not chronically; inhibition of VEGF signaling
can lead to 50–60% of tumour vasculature inhibition. However, after
discontinuing treatment, the empty “vascular sheets” of collagen that
used to host the vessels quickly become repopulated bynewendothelial
sprouts (Fig. 2C). This suggests that the undisturbed basement mem-
brane, as well as the continued presence of pericytes in those vascular
sheets, promote tumour re-vascularisation. Thus, it is now recognised
that efﬁcient therapies against tumour angiogenesis should target
both ECs and pericytes (Mancuso et al., 2006).
PDFG receptor inhibitors such as Imatinib are also used as tumour
anti-angiogenic therapies. Many clinical trials are currently evaluating
the efﬁciency of anti-PDGF therapies on various cancers (reviewed in
Heldin (2013)). For example, it has been shown that treatment of lym-
phomas with Imatinib inhibits angiogenesis. Imatinib appears to act on
vascular mural cells which leads to the disruption of the integrity of the
tumour blood vessels (Ruan et al., 2013). A study on the effect of mTOR
inhibition with the drug Everolimus in conjunction with the PDGF re-
ceptor antagonist Nilotinib in gastric cancer has shown interesting re-
sults. While PDGFr inhibition did not lead to decreased tumour
growth, andmTOR alone did not decrease tumour angiogenesis, a com-
bination of the two caused decreased pericyte coverage, decreased stro-
mal reactivity and decreased tumour growth (Onoyama et al., 2013).
However, anti VEGF-PDGF therapies are not a guaranteed success.
Inhibition of VEGF and PDGF by bevacizumab and sunitinib respectively
did not inhibit angiogenesis of glioma xenografts more effectively than
VEGF inhibition alone (Navis et al., 2011). This failure of PDGF signaling
inhibitors to enhance anti-VEGF therapy could mean that PDGF antago-
nism is not sufﬁcient to disrupt pericyte function in the tumour vascula-
ture. Recently, new targets have been identiﬁed and are gathering
attention as possible therapies
One such novel anti-angiogenic target is Olfactomedin-like 3
(Olfml3), a member of the BMP family. Olfml3 is produced by both
ECs and pericytes, is secreted in the perivascular region and has pro-
angiogenic properties. Inhibition of Olfml3 in tumours has shown to af-
fect both ECs and pericytes. Blockade of Olfml3 activity with speciﬁc an-
tibodies has been shown to inhibit tumour vascularization, pericyte
coverage and tumour growth in a mouse xenograft cancer model
(Miljkovic-Licina et al., 2012).
Another strategy being evaluated is the direct disruption of
endothelium-pericyte interactions to destabilise the vasculature.
Endosialin/CD248 is expressed in tumour-associated pericytes
(Valdez, Maia, and Conway, 2012). Application of the CD248-speciﬁc
antibody MORab-004 in a mouse xenograft model caused a decrease
in primary tumour growth. Analysis of the tumour vasculature showed
an increase in smaller and non-functional microvessels. MORab-004
treatment induces internalization of CD248 by pericytes, which
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that CD248 acts as a scaffold or guide for tumour microvasculature
(Rybinski et al., 2015).
Another elegant strategy involving pericytes does not try to destroy
cancer pericytes per se, but use their speciﬁc properties to target tu-
mours. An interesting new concept in the ﬁeld of anti-angiogenic tu-
mour treatment is to induce a so-called “tumour infarction”, where
the tumour vasculature is blocked. These infarcts are induced by admin-
istering a truncated version of Tissue Factor (tTF), which has the ability
to induce thrombosis (Huang et al., 1997). Brand et al. have used both
the leaky properties of tumour endothelium and speciﬁc pericyte
markers to target tTF to tumour sites. Pro-angiogenic cancer pericytes
express the surface proteoglycan NG2. Treatment of tumour-grafted an-
imals with a tTF-NG2 antibody fusion protein have shown that tTF can
be delivered to the tumour vasculature, can activate coagulation within
the microvasculature and inhibit tumour growth (Brand et al., 2016).
Guan et al. have also usedNG2 to target an anti-tumoural drug to the tu-
mour site. They have developed a system by which a nanoparticle con-
jugated to a peptide recognising a NG2 epitope can be directed to the
tumour site. This group has shown that their TH10-nanoparticle con-
taining the anti-mitotic drug docetaxel targets cancer pericytes and is
then internalized. This internalization causes cancer pericyte cell
death and a marked decrease in tumour angiogenesis (Guan et al.,
2014).
Counterintuitively, certain therapeutic targets increase pericyte cov-
erage to normalize tumour vasculature. Inhibition of either TRPV4 or
Ang2 in mouse Lewing lung carcinoma or mouse glioblastoma
multiforme respectively decreased tumour growth while increasing
pericyte coverage (Adapala et al., 2016; Scholz et al., 2016; Thoppil
et al., 2016). Increased pericyte coverage of the tumour vasculature de-
creases the permeability of the vessel thus limiting the access of the tu-
mour to pro-inﬂammatory and pro-tumourigenic cells.
Another important player in tumour vasculogenesis are CSCs, which
can take on the role of pericytes and contribute to the formation of new
vessels. As previouslymentioned, theNotch signaling pathway is an im-
portant regulator of CSCs. G-secretase inhibitor (GSIs) can be used to in-
hibit the Notch membrane proteins, thus blocking Notch signaling.
Treatment of glioblastoma tumours with GSIs led to the depletion of
stem-like cells in the tumour and to a decrease in tumour growth (Fan
et al., 2010).
In the last ten years, microRNAs have been gatheringmore attention
in the ﬁeld of cancer therapeutics. While endothelial and angiogenesis-
related microRNAs are well characterized, very little is known about
pericyte-speciﬁc microRNAs (Kuninty, Schnittert, Storm, and Prakash,
2016). It would be interesting to see in the future if the selective disrup-
tion or activation of certain microRNAs could contribute to the inhibi-
tion of tumour angiogenesis.
5.1. The blood brain barrier, pericytes and drug delivery to the CNS
The BBB is a specialised structure composed of ECs, astrocytes,
microglial cells, neuronal projections and pericytes. Previously it has
been shown that the molecules diffusing through the BBB appear to
be lipophilic, smaller than 600 Da in size, with or without a speciﬁc af-
ﬁnity for endogenous cell transport receptors (Pardridge, 2007).
Pericytes are very important to support cells for this endothelial bar-
rier and are essential for competent BBB function (Daneman, Zhou,
Kebede, and Barres, 2010). In a pericyte-deﬁcient mouse model, it has
been shown that pericytes contribute to the BBB by regulating gene ex-
pression patterns in ECs and by inducing polarization of astrocyte end-
feet surrounding CNS blood vessels (Armulik et al., 2010). It has also
been shown, in an in vitro co-culturemodel of BBB, that pericytes are es-
sential for BBB function. Indeed, the addition of pericytes to an EC
monolayer increased transendothelial resistance and decreased lipo-
philic molecule permeability (He, Yao, Tsirka, and Cao, 2014b), partly
by increasing the expression of the protein occludin, the maincontributor to the tight-junction organisation (Dohgu et al., 2005). In-
terestingly, pericytes can themselves actively participate in allowing
both molecules and cells through the BBB. The pericytes can act as an
“enzymatic barrier” by secreting different peptidases that can break
down protein and high-molecular weight peptides, preventing them
from crossing to the brain (Omidi and Barar, 2012). Moreover, pericytes
are involved in the recruitment of neutrophils to the sub-endothelial
layer and the breaching of the vascular wall by secreting the
chemoattractant IL8 and the metalloproteinases MMP-2 and MMP-9,
which break down endothelial cell-to-cell contacts (Proebstl et al.,
2012; Pieper, Pieloch, and Galla, 2013). Pericytes can also play a role
similar to macrophages. They express scavenger receptors that bind
various antigen-bound antibodies. This activates phagocytosis, allowing
the pericytes to clear cellular debris and parasites (Jansson et al., 2014).
As previously mentioned, the BBB is a major barrier to the many
molecules that could negatively affect the CNS. Unfortunately, this ex-
quisitely regulated system is a hindrance when pharmaceutical com-
pounds need to be delivered to the CNS. Currently, close to 98% of
small molecule and 100% of large molecule drugs on the market do
not enter the brain or cannot achieve concentrations needed for thera-
peutic beneﬁts (Pardridge, 2007). Current strategies to deliver drugs
to the brain include improved lipophilicity of the compound, lipid/ves-
icle packaging of the active agent, targeting speciﬁc transporters by
linking to a receptor ligand, “trojan horse” mimic or direct disruption
of the BBB. Most of these strategies focus on the endothelial barrier it-
self, and very few studies target the other cell types forming the BBB
(Banks, 2016). It is plausible that a shift in focus to the cells regulating
the endothelial barrier could have substantial beneﬁts on future strate-
gies in drug design. One could take advantage of the increased trans-
endothelial “leakiness” encountered when BBB pericytes are receiving
inﬂammatory signals (Banks, 2016). Conjugation of drugs to antibodies
could capitalise on the macrophage-like activity of the BBB pericytes by
activating phagocytosis, thus bringing the active compound further
through the barrier (Banks, 2016).6. Concluding remarks
In the last twenty years, our knowledge of pericytes has evolved con-
siderably. Pericytes have been better characterized and isolated from
several tissues, revealing universal and tissue-speciﬁc functions. More-
over, pericytes have been shown to have a multipotent lineage ability,
similar to other perivascular populations such as MSCs and adventitial
progenitor cells, with which they share common markers and proper-
ties. These heterogeneous populations could be grouped as PSCs. This
characteristic favours the usage of PSCs in the ﬁeld of regenerativemed-
icine and tissue engineering. However, it is still not completely clear
how PSCs are related among themselves and which one could be the
most appropriate for cell therapies. The different tissues of origin, the
differences in functions and phenotype and the lack of standardization
in the clinical trials so far call for an urgent basic science quest to resolve
these concerns. There is a risk of repeating the samemistakes seen with
vascular progenitor populations isolated from peripheral blood or bone
marrow. The lack of scientiﬁc consensus on characterization and stan-
dardization in isolation protocols, use in in vivo animal model and in
clinical trials has led to a large amount of data that is challenging to an-
alyse collectively (Ikebe and Suzuki, 2014; Ullah, Subbarao, and Rho,
2015).
As per phenotypic and functional characterization, the knowledge of
pericyte involvement in pathobiological events has grown exponential-
ly in recent years. If the succession of pathological events, well-
established in diseases such as diabetes, is observed in other diseases,
new pathobiological scenarios will appear. For instance, the ability of
pericytes to differentiate into ﬁbroblast cells supports their involvement
in post-ischemic ﬁbrosis (Birbrair et al., 2014). The stem cell-like nature
of pericytes has emerged in their relationship with CSCs, along with
39D. Ferland-McCollough et al. / Pharmacology & Therapeutics 171 (2017) 30–42their immunomodulatory properties, providing new explanations for
pharmacological resistance (Ullah et al., 2015).
In light of these discoveries, new speciﬁc therapeutic approaches
have been developed. The afﬁnity of pericytes with MSCs has led to
the use of the latter in clinical trials in patients who suffer from retinop-
athy. In tumours, pericytes, alongwith ECs, have become a major target
of anti-angiogenic therapies. Moreover, the discovery of particular sig-
naling pathways, such as the Notch-related pathway, allows the devel-
opment of novel approaches that can be used in a multi-strategic co-
adjuvant cancer therapy. In addition, diseases such as diabetes can pro-
vide an epigenetic modiﬁcation to PSCs, which may be a key factor in
cell therapy based regenerative medicine treatment (Gubernator et al.,
2015).
For all these reasons, we would like to underline the importance of
three pivotal ﬁelds that should be thoroughly investigated in pericyte
biology in the future:
a) Characterization of pericyte sets and subsets, embryological origin,
and location in the hierarchy of stem and progenitor cells in adult
tissues.
b) Novel signaling pathways affected in pathological events, which
could represent novel targets for disease treatments.
c) Standardization of methods for the use of pericytes in clinical trials.
Accordingly, pericytes, for a long time an overlooked player in
pathobiology, could become a candidate for better tailored therapeutic
treatment, as well as a powerful tool for tissue engineering and
regeneration.
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